Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Research Area
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
Orvepitant is a neurokinin-1 (NK1) receptor antagonist (Ki = 0.06 nM for the human receptor).1 It is selective for the NK1 receptor over a panel of 67 transporters, ion channels, and enzymes at 10 µM. Orvepitant inhibits substance P-induced calcium release in CHO cells expressing the recombinant human NK1 receptor (apparent pKB = 10.3). It inhibits GR73632-induced foot tapping in gerbils with half-maximal inhibitory dose (ID50) values of 0.11, 0.09, 0.09, and 3.36 mg/kg when administered 1, 4, 8, or 24 hours prior to GR73632, respectively. Orvepitant also inhibits GR73632-induced hindlimb scratching in gerbils.2 It reduces the number of territorial postures in the human threat test in marmosets, indicating anxiolytic-like activity, when administered at doses of 1, 3, and 10 mg/kg.1
WARNING This product is not for human or veterinary use.
1. Identification, biological characterization and pharmacophoric analysis of a new potent and selective NK1 receptor antagonist clinical candidate. Bioorg. Med. Chem. 21(21), 6264-6273 (2013).
2. Neurokinin-